Neither drug interfered with cell-intrinsic antiviral immune mechanisms, like IFN induction, APOBEC induction, or chemokine induction, thereby showing great potential for treatment options of COVID-19 while maintaining the host’s antiviral immune response. The gene discussed is IFNA1; the disease is COVID-19.